Assess whether pediatric studies are necessary or waivable (24e808)

Situation

The desk packet is phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division. Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan has to name Pediatric studies are necessary or Waivable for this Pharma & Life Sciences Clinical and Evidence Strategy file.

Decision

Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose Pediatric studies are necessary / Waivable using phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division.

Hypotheses to test

• Pharmacovigilance medical reviewer can defend Pediatric studies are necessary from phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge.
• Pharmacovigilance medical reviewer cannot defend Pediatric studies are necessary from phase-3 protocol with endpoint-sensitivity issues; Waivable is what the extract actually supports after a boxed-warning proposal from the review division.
• A boxed-warning proposal from the review division never reached the population in phase-3 protocol with endpoint-sensitivity issues — reopen intake, do not close pediatric studies are necessary.
• Two facts in phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division conflict for pharmacovigilance medical reviewer; hold this Clinical and Evidence Strategy file.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read phase-3 protocol with endpoint-sensitivity issues against a boxed-warning proposal from the review division and write the one fact that would move pediatric studies are necessary for pharmacovigilance medical reviewer.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (phase-3 protocol with endpoint-sensitivity issues after a boxed-warning proposal from the review division). The follow-on Clinical and Evidence Strategy action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.